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Abstract
The MST1R gene is overexpressed in pancreatic cancer producing elevated levels of the RON 
tyrosine kinase receptor protein. While mutations in MST1R are rare, alternative splice variants 
have been previously reported in epithelial cancers. We report the discovery of a novel RON 
isoform discovered in human pancreatic cancer. Partial splicing of exons 5 and 6 (P5P6) produces 
a RON isoform that lacks the first extracellular immunoglobulin-plexin-transcription (IPT) 
domain. The splice variant is detected in 73% of pancreatic adenocarcinoma patient derived 
xenografts and 71% of pancreatic cancer cell lines. Peptides specific to RON P5P6 detected in 
human pancreatic cancer specimens by mass spectrometry confirms translation of the protein 
isoform. The P5P6 isoform is found to be constitutively phosphorylated, present in the cytoplasm, 
and it traffics to the plasma membrane. Expression of P5P6 in immortalized human pancreatic 
duct epithelial (HPDE) cells activates downstream AKT, and in human pancreatic epithelial nestin-
expressing (HPNE) cells activates both the AKT and MAPK pathways. Inhibiting RON P5P6 in 
HPDE cells using a small molecule inhibitor BMS-777607 blocked constitutive activation and 
decreased AKT signaling. P5P6 transforms NIH3T3 cells and induces tumorigenicity in HPDE 
cells. Resultant HPDE-P5P6 tumors develop a dense stromal compartment similar to that seen in 
pancreatic cancer. In summary, we have identified a novel and constitutively active isoform of the 
RON tyrosine kinase receptor that has transforming activity and is expressed in human pancreatic 
cancer. These findings provide additional insight into the biology of the RON receptor in 
pancreatic cancer and are clinically relevant to the study of RON as a potential therapeutic target.
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 INTRODUCTION
While there have been recent advances in the use of cytotoxic therapy to treat pancreatic 
cancer, molecularly targeted treatments have yet to make an impact in the clinic. To develop 
effective therapeutics for a disease with few treatment options, the molecular structure and 
function of proteins expressed in pancreatic cancer must be identified and understood. RON 
is a growth factor receptor belonging to the MET family which has been suggested as a 
putative target for cancer therapeutics 1, 2. RON signaling impacts not only the cancer cell 
but is a regulator of the tumor microenvironment thru its effects on tumor-associated 
macrophages 3, 4. Currently, a monoclonal antibody (RON8, ImClone) and small molecule 
inhibitors are in Phase 1 trials and various stages of pre-clinical development, 
respectively 5, 6.
RON is expressed at minimal levels in normal pancreatic tissue, but is overexpressed in 
pancreatic and epithelial cancers of the breast, colon, lung, and prostate2. During multistep 
carcinogenesis from low to high grade pancreatic intraepithelial neoplasia (PanIN), RON is 
increasingly expressed 7. Overall the protein is expressed in 69-96% of pancreatic cancer 
specimens 7, 8. Upon receptor activation, the MAPK and AKT signaling pathways are but 
two of the downstream targets activated to promote survival, motility, tumor growth and 
invasion of cancer cells in vivo 9-11.
The full length RON protein is 1400 amino acids and is translated as a single pro-protein 
which is cleaved into an α and β subunit to form the extracellular sema domain12. The sema 
domain recognizes the receptor ligand, Macrophage Stimulating Protein (MSP), and binding 
subsequently activates the intracellular tyrosine kinase domain 13. RON is activated when 
two receptor molecules form a homodimer and bind one MSP ligand molecule 14. When the 
receptor is overexpressed, interactions between the extracellular portions of the receptor 
cause dimerization and is hypothesized to be the mechanism of ligand independent 
activation.
RON is rarely mutated, but alternative splicing events are common as the gene transcript is 
increasingly overexpressed. Approximately eight different RON isoforms have been 
described in various epithelial cancer types 15. Exon skipping is the most common splicing 
event, creating RONΔ165 and RONΔ160 where exon 11 and exons 5+6 are skipped, 
respectively 16, 17. A short form of RON is produced by an alternative promoter and 
transcription start site in intron 10, producing a protein that lacks the entire extracellular 
domain 18. In breast cancer, short form RON overexpression specifically activates the PI3K 
signaling pathway which results in increased tumor growth, epithelial to mesenchymal 
transition (EMT), and increased metastasis 19. Each of these three isoforms is constitutively 
phosphorylated and contributes to an increasingly invasive phenotype.
Several preclinical studies have demonstrated robust antineoplastic activity following RON 
inhibition and form the basis for development of therapeutics targeted to the 
receptor 9, 20, 21. Understanding the biology of RON isoform splice variants will allow us to 
more effectively evaluate current therapeutics and develop new, targeted therapies. In this 
study we identified a novel RON isoform produced by alternative splicing of exons 5 and 6. 
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Alternative 5’ and 3’ splice sites produce a transcript and protein product that omits a 
portion of exons 5 and 6 (P5P6). We demonstrate that P5P6 protein is expressed in human 
pancreatic cancer specimens and it transforms immortalized human pancreatic ductal 
epithelial cells such that they become tumorigenic in vivo.
 RESULTS
 Identification of a novel RON splice variant in pancreatic cancer
Previous studies in colon cancer and glioma revealed that RON isoforms are often generated 
based on alternatively spliced transcripts between exons 4 and 7 17, 22, 23. As no study to 
date has explored alternative splicing of RON in human pancreatic cancer, we sought to 
determine if those alternative splicing events previously identified were present. Initially, we 
analyzed RNA from a human pancreatic cancer by end point PCR to amplify a region of 
RON between exons 4 and 7 (Figure 1A). Sequencing the resulting bands confirmed that 
they were specific for the full length protein, exon 6 skipping (RONΔ90), partial exon 5 and 
partial exon 6 skipping (P5P6), and exon 5 and 6 skipping (RONΔ160). To our knowledge, 
the RON P5P6 splice variant has not previously been identified in any tumor type. This 
novel isoform is produced by an alternative 5’ splice site within exon 5 and an alternative 3’ 
splice site within exon 6. Splicing is in frame and compared to the full length protein 
produces a transcript which has skipped 195 nucleotides (Figure 1B).
The P5P6 protein product is 1335 amino acids, yielding a molecular weight of 145 kDa for 
the pro-P5P6 and 112 kDa for the cleaved β-subunit. Omission of this 65 amino acid 
sequence corresponds to loss of the first Immunoglobulin-Plexin-Transcription (IPT) domain 
(Figure 1C). A similar region is also deleted in the RON variant Δ160 that is expressed in 
colon and breast cancer 17, 24. Three cysteine residues are removed by deletion of these 
amino acids that function to produce intermolecular disulfide bonds. Deletion of these 
cysteine residues is functionally significant and in RONΔ165 produces unbalanced bonds 
and RON oligomer formation 16.
We next determined whether the P5P6 isoform could be identified in normal pancreatic 
tissue and what the prevalence of P5P6 expression is in pancreatic cancer. First we 
performed PCR using primers specific for the P5P6 junction as well as total RON transcripts 
using primers directed at the C-terminus (Figure 2A). These studies revealed that P5P6 
transcript could not be identified in normal pancreas, but was detected in 73% of PDX and 
71% of cell lines (Figure 2B).
Next we quantified the amount of RON mRNA being produced using absolute quantitative 
Real Time PCR in both patient-derived xenografts (PDX) and pancreatic cancer cell lines. 
There are no commercial antibodies specific to isoforms of RON therefore we could not 
quantitate isoform protein expression using traditional methods. Plasmids containing full 
length RON and P5P6 transcripts were used to generate standard curves (Supplementary 
Figure S1). Efficiency was calculated at 106% for RON c-terminal primers and 91% for the 
P5P6 primer pair. We found that whole normal pancreas expresses 67 copies of total RON 
transcripts per 73 ng of RNA and reaffirmed the absence of P5P6 expression (Figure 2C). 
We demonstrated quantitatively for the first time that the magnitude of RON overexpression 
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at the RNA level is 150-400 times that present in normal pancreatic tissue. Similarly, 
pancreatic cancers also generated high copy numbers of P5P6 transcript ranging from 1304 
– 4215 copies per 73 ng of RNA or 20-70 fold greater abundance than total RON transcript 
seen in normal tissue. Cell lines that overexpress RON (Bx-PC3, AsPC1, 79E, 34E) also 
generated high copy numbers of P5P6 transcript.
 P5P6 protein can be detected by mass spectrometry
While we have demonstrated that the P5P6 transcript was abundant in pancreatic cancer 
specimens, any putative biologic consequences of P5P6 are predicated on translation to a 
functional protein. We first utilized a non-specific RON antibody (C-20) to the c-terminal 
portion of the β chain to determine RON expression pattern in PDXs. Although some PDXs 
give a western blot signal around 115 kDa (Red arrow in Figure 3A), there is no certainty 
that this corresponds to the P5P6 protein (Figure 3A).
We therefore utilized mass spectrometry to investigate the presence of P5P6 protein in 
pancreatic cancer based on the finding that RON isoforms produce unique peptide fragments 
after digestion with trypsin (Figure 3B). Each isoform protein sequence was analyzed by the 
ExPASy PeptideCutter tool that predicts peptides generated after trypsin digestion 25. 
Immunoprecipitation of two PDXs (1713 and 1444) was performed with an antibody 
specific for the C-terminal portion of RON (E9) and the N-terminal portion (RON8). There 
was adequate protein pulled down as seen on a stained gel and RON peptides were the most 
common in the sample (Supplementary Figure S2). Ultimately, PDX 1713 contained a 
peptide unique for the P5P6 protein (Figure 3C). None of the remaining peptides that were 
identified were isoform specific (Figure 3D). This proves that generation of the P5P6 
transcript results in translation to P5P6 protein in pancreatic cancer. P5P6 protein 
identification suggests it is present in relatively high abundance compared to other isoforms 
whose unique peptides could not be detected using this methodology.
 The P5P6 isoform induces oncogenic phenotypes
To understand its effects on cancer cell biology we cloned the RON P5P6 cDNA into full 
length RON mRNA and attached it to enhanced Green Fluorescent Protein (eGFP). This 
recreated the partial exon 5 and 6 splicing and created the P5P6-eGFP (P5P6e) fusion 
protein. This was transfected into HPDE, Human Pancreatic Nestin-expressing Epithelial 
(HPNE), COS-1 (Cos), and MiaPaca2 (MP2) cell lines using a lentiviral vector. HPDE 
expresses low levels of full length RON while HPNE, Cos, and MP2 were chosen as they do 
not express detectable RON protein. RON P5P6e expression and phosphorylation levels 
were stable throughout all experiments. HPDE P5P6e expressing cell lines displayed no 
obvious change in morphology in culture (Figure 4A). The P5P6e protein primarily localizes 
to the cytoplasm in a reticular pattern surrounding the nucleus and to the plasma membrane 
(arrows, Figure 4B). We also created an untagged version RON P5P6 cDNA and expressed it 
in HPDE cells to rule out any effects of the fusion protein on oncogenic phenotypes 
(Supplementary Figure 3).
Western blot of the stably transduced cell lines show that the P5P6 protein is detectable by 
conventional RON β antibodies (Figure 4B). In all cell lines, it produces a similar pattern of 
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two bands which are an uncleaved pro-form (172 kDa) and a cleaved β chain (139 kDa). The 
HPDE P5P6e cell line expresses somewhat higher levels of the fusion protein and 
subsequent degradation products can be seen (shown is a less exposed blot, red arrows 
Figure 4C). Immunoblot for the α subunit of RON confirms that P5P6 is cleaved into 
separate subunits similar to the full length protein. Immunoprecipitation with RON β 
antibody and immunoblot with phosphotyrosine (pY) shows that the RON P5P6 protein is 
constitutively phosphorylated. In the HPDE cell line the degradation products are also still 
phosphorylated as the N terminal part of the β chain is cleaved (red arrows). Importantly, the 
level of P5P6e protein expressed in the HPDE and HPNE cell lines is similar to the 
overexpression of total RON in 3 pancreatic cancer cell lines and 3 PDXs (Figure 4D). This 
demonstrates these cell lines are producing physiologic levels of RON protein comparable to 
that seen in human pancreatic cancers and cell lines.
In HPDE cells AKT is active at baseline and RON P5P6 increased phosphorylation by 2 
fold. However there were no significant effects on ERK phosphorylation (Figure 5A). 
Parental HPNE cells do not express RON, however when RON P5P6e is expressed both the 
AKT and MAPK pathways are activated. In contrast, in MP2 cells there was a modest 
increase in MAPK signaling while minimal changes were noted in Cos cells, strongly 
suggesting the effects of P5P6 are cell and context specific. We also noted that in HPDE 
cells, MSP stimulation did not change phosphorylation of P5P6 and appeared to alter 
downstream signaling only through the native full-length RON receptor (Figure 5B).
RON is under investigation as a therapeutic target and BMS-777607 is a MET family 
inhibitor which effectively inhibits RON signaling in pancreatic cancer 30. Treatment with 
BMS-777607 at 3 μmol/L completely inhibited phosphorylation in the HPDE P5P6e line 
that could not be rescued with MSP stimulation (Figure 5C). Signaling through AKT was 
significantly reduced and there was no effect on MAPK. Since BMS-777607 is not a highly 
specific RON inhibitor, the effects on signaling are obviously not necessarily secondary to 
P5P6 inhibition alone.
 RON P5P6 isoform signaling is distinct from RONΔ160 and full length RON
The P5P6 isoform is most similar in structure to RONΔ160 that results from complete 
skipping of exons 5 and 6. The mechanism of RONΔ160 induced oncogenesis involves 
accumulation of β-catenin, which is required for isoform mediated cell transforming 
activities 26. We observed no accumulation of total β-catenin in the P5P6e expressing cell 
lines (Figure 5D). STAT3 is a transcription factor implicated in multiple stages of KRAS 
driven cancer progression 27. STAT3 is activated when full length RON is stimulated with its 
ligand MSP, and high levels of STAT3 phosphorylation were correlated with high levels of 
RON expression in gastroesophageal adenocarcinoma 28. In contrast, we found that RON 
P5P6 expression does not activate STAT3 signaling (Figure 5E). Conversely, in the Cos and 
MP2 lines there is a loss of total STAT3 and a concordant decrease in phosphorylation. 
These experiments suggest that P5P6 signaling is mechanistically distinct from both RON 
Δ160 and the full length protein as the β-catenin and STAT3 pathways are not downstream 
targets.
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 P5P6 is transforming and induces oncogenic phenotypes
We next performed functional assays to determine if P5P6e signaling induced an oncogenic 
phenotype. We found no differences in proliferation between the HPDE P5P6e, MP2 P5P6e 
and their parental lines, a finding consistent with prior studies of RON signaling in 
pancreatic cancer cells (Supplementary Figure S4A). Wound closure assay showed HPDE 
P5P6e expressing cells induced significantly greater wound closure at all time points. At 72 
hours the extent of wound closure was 93% and 66% (P < .001) for the HPDE P5P6e 
expressing and parental HPDE line respectively (Figure 6A). Interestingly, in the poorly 
differentiated MP2 cell line, P5P6e cell line slightly decreased wound closure at all times 
points again suggesting the contextual relevance of P5P6 activity (Supplementary Figure 
S4B). We have previously demonstrated that RON signaling activates VEGF production by 
pancreatic cancer cells via the MAPK pathway 29. While we noted a 36% increase (263 
pg/mL vs 194 pg/mL, P = 0.011) in VEGF secretion in HPDE P5P6e compared to the 
parental line (Supplementary Figure 5), this increase is small and likely is not biologically 
significant.
Finally, we utilized a colony forming assay to determine whether P5P6 expression could 
transform NIH3T3 cells (Figure 6B). P5P6 expression significantly increased colonies 
formation compared to empty vector, yet the effect was more modest than expression of 
mutant KRAS. Collectively, these experiments reveal that P5P6 has transforming activity 
and enhances migration in human pancreatic duct cells. The effects on migration appear to 
be specific to the context as they are not observed either in a non-pancreatic epithelial cell 
line (Cos) or in the poorly differentiated pancreatic cancer cell line (MP2).
 RON P5P6 expression is tumorigenic in vivo
The previous series of assays suggested that expression of P5P6e in HPDE cells induced 
both molecular and phenotypic alterations. To determine if these alterations reached a 
threshold sufficient to alter in vivo biology, we used an orthotopic cell-line derived xenograft 
model. The HPDE cell line has previously been shown to be non-tumorigenic in SCID 
mice 31. We injected one million HPDE or HPDE P5P6e cells into murine pancreata as an 
orthotopic xenograft. While the parental HPDE-derived xenografts failed to induce tumors in 
ten mice after 16 weeks, the HPDE P5P6e orthotopic injections resulted in tumor formation 
in six of eight mice that were palpable after 4 weeks (p-value 0.02, Figure 7A). Expression 
of the P5P6 eGFP fusion protein was evidenced by bright tumor fluorescence. Subcutaneous 
injection assays were also performed and produced identical results (Figure 7B). Orthotopic 
tumors had a mean weight and volume of 178 mg and 156 mm3 (p-value 0.03, Figure 5C). 
One orthotopic tumor locally invaded the abdominal wall but we found no gross evidence of 
metastatic disease.
A hallmark of pancreatic cancer is the dense stromal component present within the tumors. 
We performed H&E staining and immunohistochemistry (IHC) on the P5P6e tumor sections 
to characterize tumor histology and protein expression (Figure 7D). Merged confocal images 
show the majority of the tumor was HPDE P5P6e expressing cells (Green, GFP), but that 
there was a significant stromal component to the tumors (Blue, DAPI). Ductal structures 
which express E cadherin (arrows, Figure 7D) but not the GFP fusion protein represent 
Chakedis et al. Page 6
Oncogene. Author manuscript; available in PMC 2016 July 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
residual clusters of host mouse pancreatic acinar cells. RON isoforms have been reported to 
promote epithelial to mesenchymal transition (EMT) but we did not observe significant 
morphologic evidence of P5P6 induced EMT either in vivo or in vitro. Cells maintained a 
round shape and expressed e-cadherin homogenously (Supplementary Figure S6).
 DISCUSSION
The macrophage stimulating protein receptor 1 (MST1R) gene locus contains the gene for 
RON and its splice variants on chromosome 3p21 32. This region of the genome contains 
many oncogenes and is frequently altered in many epithelial malignancies 33. During 
carcinogenesis as RON is increasingly expressed in pancreatic cancer there is subsequent 
generation of splice variants. In this study, we report the discovery of a novel RON isoform 
that is produced by partial skipping of exons 5 and 6 and is expressed in the majority of 
pancreatic cancers and pancreatic cancer cell lines. No previous reports have quantified 
levels of RON isoform production for comparison, however the amount of P5P6 transcript is 
20-70 fold times the amount of total RON expressed in normal pancreas. Quantification of 
splice variants will be important in future studies to determine if there is isoform switching 
between cancer types or during oncogenic progression.
Detection of P5P6 protein is difficult as there are no specific antibodies and the size is 
similar to the wild type protein. Despite this, we were able to confirm expression of P5P6 
protein in pancreatic cancer by detection of a specific peptide using mass spectrometry. To 
our knowledge this is the first demonstration of RON isoform protein expression in human 
cancer to be documented by a method other than immunoblotting. The P5P6 protein isoform 
has a truncation of the first IPT domain which may be a cause of its deregulation. RON 
shares domain structures with plexins, a family of semaphorin protein receptors 34. Class B 
plexins can couple with RON and MET in the absence of ligand to activate the receptor and 
promote invasive activity 35. Deletion of this domain will alter the proteins molecular 
structure leading to increased or decreased affinity for conventional RON binding partners. 
IPT domain deregulation may also contribute to constitutive activation of the protein through 
unbalanced cysteine residues. The P5P6 isoform traffics to the plasma membrane similar to 
the full length protein which allows for binding of ligand, interaction with cell surface 
receptors, and interaction with cytoplasmic binding partners. It is clear that P5P6 protein is 
phosphorylated in the absence of ligand and may be due to accumulation of P5P6 dimer 
formation and subsequent auto-phosphorylation.
Overexpression of P5P6 in the immortalized HPDE cell line resulted in increased AKT 
signaling, cell migration, and transformed the cell line to become oncogenic. The HPDE cell 
line has no mutations in the most commonly mutated genes in pancreatic cancer - p53, 
KRAS, CDKN2A, or SMAD4, though p53 is nonfunctional and there is loss of the Rb 
gene 31. The HPDE and HPNE lines are the closest representation of a normal pancreatic 
epithelium available and is a limitation to this study. The context of P5P6 overexpression 
clearly matters as the biologic changes we observed in HPDE and HPNE differ in an 
unrelated cell line (Cos) and a mesenchymal pancreatic cell line (MP2). This raises the 
possibility that P5P6 expression may exert biologic effects early in oncogenesis rather than 
after the accumulation of multiple mutational events. This study has limitations in that 
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functional studies rely on P5P6 overexpression. However, total RON levels in P5P6 lines are 
similar to pancreatic cancer cell lines and human samples. Furthermore, our qPCR transcript 
quantification is an average of all cell types contained within the tumor. In pancreatic cancer 
stromal cells represent 50-90% of the tumor volume and physiologic levels of RON P5P6 
transcripts in the malignant epithelial cells are likely much higher than we have detected 36.
The discovery of novel RON protein isoforms has potential translational impact. Full length 
RON expression has been shown to be a prognostic marker for several cancers, but not for 
resectable pancreatic cancer 28, 37. Use of RON as a predictive or prognostic marker may 
require consideration of its isoforms to make valid correlations. RON P5P6 is constitutively 
active and does not need ligand to interact with other proteins or signal. Monoclonal 
antibody therapies that prevent binding of ligand to the receptor and subsequent activation 
may therefore be ineffective against some RON isoforms. Small molecules may therefore be 
more broadly effective in inhibiting RON and its isoforms. In fact, we found that 
BMS-777607 inhibited P5P6 phosphorylation and decreased AKT signaling. Our findings 
for the P5P6 isoform are consistent with previous studies that suggest alteration of the IPT 
domain structure effects RON function in profound ways. Therapies that target these 
interactions may be of interest as modulators of full length RON and RON isoform 
signaling.
In summary, this study identified a new RON isoform, P5P6, which is commonly expressed 
in pancreatic cancer. Overexpression of the isoform transforms NIH3T3 cells and 
immortalizes, non-tumorigenic human pancreatic ductal epithelial cells. Initial studies into 
the mechanism of its action imply signaling mechanisms distinct from the full length protein 
and a structurally similar isoform. Ultimately discovery of this isoform supports previous 
studies suggesting that RON isoform expression is important in cancer initiation and 
tumorigenesis. Therapeutics directed at the RON receptor will be most effectively evaluated 
if isoform activity is considered. Future work will be directed at further characterizing 
expression of RON isoforms in pancreatic cancer to understanding their functional 
significance and susceptibility to therapeutic agents.
 MATERIALS AND METHODS
 Human Tissues
All human tissues were collected and utilized in accordance with IRB approved and IACUC 
approved protocols at the University of California, San Diego. Tumor tissue was implanted 
into the pancreas of NOD SCID Gamma (NSG) mice as described previously 38, 39. Patient 
Derived Xenografts (PDX) were established and passaged after they were at least 10mm in 
size. Low passage (<5) tumors were used for analysis.
 PCR
Trizol (Invitrogen) was used to extract total RNA from PDXs. A cDNA library was created 
using SuperScript III Reverse Transcriptase (Invitrogen) and PCR used RedTaq DNA 
Polymerase (Sigma). The following primers were used:
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RON Exon 4 to 7: Forward – GGCATGGCATTTCATGGGCT, Reverse - 
AGAGTCTGTCTGTAGGCACC
RON C-Terminal : Forward – TAGTGTCTGCACTGCTTGGG, Reverse - 
GCTGTTCTGGACGCACATTC
RON P5P6 specific: Forward – GGCAGTACAAGGCCTACCAA, Reverse - 
TCAGTCCCATTGACCAGCAC
 Quantitative real-time PCR
All reactions used SsoFast EvaGreen Supermix (Bio-Rad), primers (375nM final 
concentration), 1 μL of cDNA (corresponding to 73 ng of RNA). Absolute quantification 
used methods previously described 40. A plasmid containing the full length RON and RON 
P5P6e mRNA was used to generate a standard curve using RON c-terminal and P5P6 
specific primers respectively. The equation DNA MW (g) = ((# of bp) × (660 g/mol/bp))/ 
6.022×1023 particles/mol was used to convert plasmid size to weight. Weight was used to 
construct a serial dilution of 107 – 102 plasmid copies. Standards were run in duplicate on 
each plate used to analyze unknown samples and linear standard curve was generated 
(Supplementary Figure S1). The slope of the lines corresponds to the efficiency of the 
reaction using equation Efficiency = (10−1/slope−1) × 100%.
 Immunoprecipitation, Western Blot, and Immunohistochemistry
Pancreatic tumors of approximately 100mg or cultured cells at approximately 80 % 
confluency were used to make protein lysates in RIPA buffer. Immunoprecipitation (IP) was 
performed using RON C-terminal (E9, Santa Cruz) or RON N-terminal (RON8, ImClone). 
For western blot primary antibodies used are RON β (C20, Santa Cruz), RON α (EP1132Y, 
Abcam), Phosphotyrosine (4G10, Millipore), Actin (A2066, Sigma), Phospho-AKT 
(9271,Cell Signaling), AKT (9272, Cell Signaling), Phospho- p44/42 MAPK (9101, Cell 
Signaling), p44/42 MAPK (9102, Cell Signaling), Phospho-β-catenin (Tyr-654, ECM 
Biosciences), β-catenin (8480, Cell Signaling), Phospho-Stat3 (9138, Cell Signaling), Stat3 
(4904, Cell Signaling). For immunohistochemistry the antibodies used were GFP 
(NB100-1770, Novus Biologicals) and E-cadherin (610182, BD). ImageJ program was used 
for densitometry.
 Mass Spectrometry Sample preparation and LC-MS-MS
Immunoprecipitation was performed on 3 mg of protein with RON c-terminal (E9, Santa 
Cruz) and RON N-terminal (RON8, Imclone) then beads were submitted and sample 
preparation performed as previously described 41. Trypsin-digested peptides were analyzed 
by high pressure liquid chromatography (HPLC) coupled with tandem mass spectroscopy 
(LC-MS/MS) using nano-spray ionization 42. The nanospray ionization experiments were 
performed using a TripleTof 5600 hybrid mass spectrometer (ABSCIEX) interfaced with 
nano-scale reversed-phase HPLC (Tempo). The collected data were analyzed using 
MASCOT® (Matrix Sciences) and Protein Pilot 4.0 (ABSCIEX) for peptide identifications. 
RON isoform protein sequences are not normally included in the Protein Pilot analysis 
software and were supplemented in order to determine their detection.
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 Molecular Cloning and Lentiviral Transfection
The P5P6 protein transcript was created by recreating the P5P6 splicing event in the full 
length RON cDNA which had previously been attached to GFP. The region between exons 3 
and 8 was amplified using the primers (F – GGGACCAGGTTTTCCAGGTACC and R – 
GGTACCTGGTTCCTGGACCTTCCAG) from a primary pancreatic cancer sample. The 
PCR amplicon was TA cloned using a PCR Cloning Kit (Qiagen) and competent DH5α E. 
Coli (Invitrogen). The full length RON+eGFP vector and the P5P6 containing vector were 
cut with specific endonucleases HindII and KpnI (NEB) and ligated using T4 DNA Ligase 
(NEB). DNA sequencing confirmed correct P5P6 sequence and the cDNA was then 
transferred into a lentiviral plasmid for transfection. After transfection selective puromycin 
media was used and the TE300 inverted fluorescence microscope (Nikon) was used to 
screen for green fluorescence.
 Functional Assays
For scratch wound assay, 1×106 cells were plated in a 6-well dish and allowed to attach and 
grow to confluency. A 1 mL aspirating pipette tip was used to create 3 vertical scratches in 
each well. Images were taken at 4× magnification with Nikon TE300 inverted fluorescence 
microscope. Metamorph (Molecular Devices) analysis software was used to outline and 
determine wound area. Scratch assay was performed three separate times and all data 
combined. NIH 3T3 cells were stably infected with pCDH CMV empty vector, P5P6-eGFP, 
or KRAS G12V plasmid and plated. After 2 weeks cells were fixed, stained with crystal 
violet and a Keyence BZ-X710 microscope scanned the well and counted purple colonies.
 Cell Lines and Orthotopic Injections
The Human Pancreatic Ductal Epithelial (HPDE) cell line was a generous gift from Dr. 
Ming Tsao and the University Health Network and cultured in Keratinocyte-SFM (Gibco) 
with epidermal growth factor and bovine pituitary extract, and antibiotic-antimycotic 
(Gibco)43. MiaPaca2 and Cos1 cell lines were obtained from ATCC and cultured in DMEM 
(Corning) supplemented with 10% fetal bovine serum (Sigma). HPNE cells were obtained 
from Dr. Klemke at UCSD and cultured in DMEM/Base F media (InCell) supplemented 
with 5% FBS. For cell injections 1×106 HPDE and HPDE P5P6e cells were resuspended in 
10 μL of PBS and mixed with 10 μL of Matrigel (BD). NSG mice were injected 
orthotopically using a 30 gauge needle. Mice were monitored for signs of distress and 
disability throughout the experiment. After 12-16 weeks mice were sacrificed and tumors 
were harvested. Tumor volume was measure as: Volume = 1/2(length × width 2). Mice and 
tumors were imaged using MVX10 (Olympus) camera and cellSens (Olympus) software.
 Statistical Analysis
All data was analyzed using SPSS Statistics v.20 (IBM) and Prism v.6 (GraphPad Software). 
Functional assay values were averaged from each cell line per time point and compared 
using one way ANOVA.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Discovery of a novel RON isoform in human pancreatic cancer. A, A novel RON isoform 
created by alternative splicing of exons 5 and 6 is discovered in a pancreatic cancer 
specimen. B, The mRNA sequence of this splice variant contains a partial 5 and partial 6 
(P5P6) exon splicing. C, There are 195 nucleotides omitted in the final protein resulting in a 
65 amino acid deletion of the first Immunoglobin-Plexin-Transcription (IPT) domain. The 
P5P6 protein contains the extracellular Sema domain and intracellular tyrosine kinase 
domain similar to the full length RON protein.
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Figure 2. 
P5P6 is expressed in the majority of pancreatic cancers. A, PCR detects the expression of 
P5P6 specific transcript in PDX samples. B, The majority of PDX and pancreatic cancer cell 
lines express the isoform. C, Absolute quantification PCR determined the number of total 
RON and P5P6 specific transcript copies in each PDX and pancreatic cancer cell line. Both 
transcripts are overexpressed in all PDX compared to normal pancreas. P5P6 copy number is 
positively correlated with total RON expression, but with variable overall percentages.
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Figure 3. 
Mass spectrometry confirms the P5P6 protein is expressed in pancreatic cancer. A, The β 
chain of RON is detected by western blot in a representative group of PDX. Pro-RON and 
full length RON (flRON) bands are prominent (black arrows), however there are different 
molecular weight bands which may correspond to expressed isoforms (grey and red arrows). 
B, After trypsin digestion RON isoforms are distinguished by unique peptides using mass 
spectrometry. C, We discovered a peptide in PDX 1713 which can only be produced by 
partial exon 5 and partial exon 6 splicing. D, Several other peptides were detected which are 
specific to RON but not specific to any isoform. This confirms protein expression of P5P6 in 
pancreatic cancer.
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Figure 4. 
P5P6 expression in human pancreatic duct epithelial cells. A, The P5P6-eGFP fusion protein 
is expressed in the HPDE cell line. Live cell imaging shows there is no change in cell 
morphology but the HPDE P5P6e cell line has a heterogeneous mix of fluorescent cells. B, 
The P5P6e protein is most abundant in the cytoplasm but some cells display plasma 
membrane localization (blue arrows). C, P5P6e protein is expressed in all three cell lines and 
is cleaved from a pro– form into α and β subunits. The isoform is constitutively active in all 
cell lines, though most heavily phosphorylated in HPDE. In the HPDE cell line, P5P6e is 
expressed at such a high level that degradation products are detectable and phosphorylated 
(Red arrows). D, The expression of P5P6e protein in HPDE and HPNE is comparable to 
total RON expression in pancreatic cancer cell lines (AsPC1, Bx-PC3, FG) and 3 PDX 
specimens.
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Figure 5. 
P5P6 induces oncogenic phenotypes in human pancreatic duct epithelial cells A, P5P6e 
expression increases AKT phosphorylation in the HPDE cell line and activates both AKT/
MAPK in HPNE. B, Stimulation with the RON ligand, MSP (100 ng/mL for 30 minutes) 
activates full length RON in the HPDE cell line but did not increase P5P6 phosphorylation. 
MSP stimulation did not change P5P6 downstream signaling. C, Small molecule RON/MET 
inhibitor BMS-777607 completely inhibited phosphorylation of P5P6 (3 μmol/L for 1 hour). 
This inhibition could not be overcome with MSP stimulation (100 ng/mL for 30 minutes). 
There is decreased AKT activation by blocking P5P6 phosphorylation, but there is no effect 
on the MAPK pathway. D, Mechanism of P5P6e tumorigenesis is distinct from RONΔ160 as 
there is no accumulation of total β-catenin. E, P5P6 signaling does not activate STAT3 
transcription factor pathway in any cell line unlike MSP stimulated full length RON 
activation.
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Figure 6. 
P5P6 transforms human pancreatic duct epithelial cells. A, Cell motility is significantly 
increased as a result of P5P6 expression in the HPDE cell lines but not in Cos or MiaPaca2 
(Supplemental Figure S2B). B, NIH 3T3 transforming assay showed transformation with 
expression of P5P6e with significantly more colonies formed than the empty vector. The 
transforming effect is not as strong as KRAS G12V mutation expression.
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Figure 7. 
P5P6 is tumorigenic when expressed in vivo. A, HPDE and HPDE P5P6e cells were injected 
orthotopically and subcutaneously into NSG mice. Only the HPDE P5P6e expressing cell 
line can form a tumor. B, All tumors expressed the P5P6 eGFP fusion protein and are 
brightly fluorescent. C, HPDE P5P6e Orthotopic mean tumor volume and weight was 
statistically significant as 6 of 8 had tumor growth (p-value 0.03). D, H+E and 
immunohistochemistry shows isoform expressing cells (Green, GFP) are mixed with a large 
stromal component (Blue, DAPI). HPDE P5P6e cells maintain morphology seen in culture 
and express E-cadherin (Red). Clusters of residual host pancreas acini are interspersed 
throughout the tumor (white arrows).
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